Search Follow us


Oncology Venture (OV) is a cancer-focused pharmaceutical company that in-licenses discontinued oncology drugs at low cost and uses its mRNA-based drug response predictor (DRP) technology to identify and treat previously unidentified patient populations most likely to respond. OV conducts these focused Phase II trials with an aim to sell or out-license the Phase III-ready drugs with their respective DRPs. OV has in-licensed six assets to date, the most advanced of which is dovitinib from Novartis. Our initial valuation is SEK823.8m or SEK59.56 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs